Pharmaceutical marketing usually focuses on what a treatment delivers. But what if its greatest value comes from what patients never have to experience? That question is reshaping how pharmaceutical companies market treatments that may reduce the need for more intensive care, especially following the FDA’s October 19, 2026, accelerated approval of GSK’s Jemperli (dostarlimab-gxly) for certain patients with locally advanced rectal cancer.
For eligible patients, the immunotherapy may provide an opportunity to avoid chemotherapy, radiation, and surgery. However, that possibility comes with important clinical conditions, treatment risks, and ongoing monitoring.
For pharmaceutical marketers, this creates an unusual challenge. How do you communicate the value of avoided treatment without promising outcomes that remain uncertain?
Table of Contents
- Why Jemperli Changes the Oncology Value Story
- How Treatment Deintensification Marketing Changes Patient Value
- How Marketers Can Communicate Avoided Treatment
- Building Trust Around Clinical Uncertainty
- Conclusion
- Frequently Asked Questions
Why Jemperli Changes the Oncology Value Story
Traditional oncology marketing often highlights survival, response rates, or improvements over existing therapies. Jemperli introduces another powerful consideration: the possibility of reducing the treatment burden.
The FDA’s accelerated approval covers adults with stage II or III locally advanced rectal cancer whose tumors are mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H), as determined by an FDA-authorized test.
These biomarkers identify a specific patient population, representing approximately 3% of locally advanced rectal cancers.
The approval was supported by the phase 2 AZUR-1 trial involving 154 previously untreated patients. Participants received Jemperli alone, with treatment planned every three weeks for up to nine cycles.
Importantly, 110 patients, or 71%, had not required additional cancer treatment and had not experienced disease progression at the interim analysis. Separately, 47% of 116 patients evaluable by independent central review achieved a sustained clinical complete response for 12 months.
These findings offer a compelling story, but they require careful interpretation.
The approval relies on an intermediate measure of treatment benefit, and the long-term risk of cancer recurrence remains unknown. Furthermore, some patients required additional therapy, while others had not yet completed sufficient follow-up.
Consequently, marketers must distinguish between the possibility of avoiding treatment and a guarantee that those interventions will never be necessary.
How Treatment Deintensification Marketing Changes Patient Value
Treatment deintensification means reducing the intensity or extent of medical treatment when appropriate clinical evidence supports doing so.
In oncology, that might involve fewer procedures, less toxic therapy, or avoiding certain interventions altogether.
For patients facing rectal cancer, the potential benefits can be deeply personal.
Chemotherapy and radiation may affect energy, fertility, and daily routines. Meanwhile, rectal surgery can carry risks involving bowel, urinary, and sexual function. Some patients also face the possibility of a permanent colostomy.
Therefore, avoiding these interventions when clinically appropriate could mean preserving important aspects of everyday life.
This creates an important shift in pharmaceutical storytelling.
Instead of focusing only on what a medication delivers, pharmaceutical marketers can highlight the treatments, side effects, and disruptions that eligible patients may be able to avoid.
However, avoiding conventional treatments does not mean avoiding all treatment burdens.
Jemperli requires intravenous infusions and can cause serious immune-related side effects, including potentially life-threatening reactions. Patients managed without surgery also require close surveillance for recurrence.
The emerging value proposition is therefore not simply less treatment. It is the potential to achieve meaningful cancer control while avoiding selected interventions and their associated burdens.
As explored in Pharma Marketing Network’s discussion of supportive care marketing, patient value extends beyond the treatment itself.
How Marketers Can Communicate Avoided Treatment
For pharmaceutical brands, communicating the value of avoided interventions requires a different creative approach.
The first opportunity is to make patient priorities more visible.
Rather than relying only on clinical charts, marketers can explain why bowel function, fertility, recovery time, and daily independence matter to people receiving cancer care.
For example, a campaign might explore the questions patients ask before starting treatment, including how therapy could affect their work, relationships, and future plans.
However, these discussions should never imply that a particular outcome is assured.
A second opportunity involves helping healthcare professionals understand appropriate patient selection.
Because Jemperli’s rectal cancer indication requires confirmed dMMR or MSI-H status, biomarker testing becomes an important part of the communication strategy.
Educational materials can explain who qualifies, what the evidence shows, and why monitoring remains essential.
Additionally, marketers should consider the broader patient journey, including referrals and specialist coordination.
Pharma Marketing Network’s examination of Centers of Excellence marketing highlights how specialized institutions can influence access to advanced therapies.
For this category, successful communication must support informed clinical conversations rather than simply generate brand awareness.
The strongest campaigns will make the potential benefit understandable without turning clinical complexity into an oversimplified promise.
Building Trust Around Clinical Uncertainty
For marketers promoting less intensive cancer treatment options, the greatest challenge may be balancing optimism with clinical evidence.
The word “avoid” is emotionally powerful. Yet it can become misleading when presented without context.
For example, saying patients may avoid chemotherapy, radiation, or surgery is different from claiming those treatments will never be needed.
That distinction matters because Jemperli received accelerated approval, and additional evidence is required to confirm its lasting clinical benefit.
According to the FDA-approved prescribing information, the long-term risk of relapse remains unknown.
Therefore, responsible messaging should clearly explain eligibility, available results, treatment risks, and ongoing follow-up requirements.
Marketers should also avoid suggesting that immunotherapy is risk-free simply because it may replace more invasive interventions for some patients.
Balanced communication can acknowledge both the potential to preserve quality of life and the serious adverse reactions associated with immune checkpoint inhibitors.
Furthermore, patient stories should reflect actual experiences without presenting individual outcomes as typical.
For brands developing patient education and professional outreach, eHealthcare Solutions offers an example of the specialized healthcare advertising environment where accurate, audience-specific communication matters.
Ultimately, trust grows when the promise of innovation is accompanied by a clear explanation of its limits.
Conclusion
Jemperli’s accelerated approval offers pharmaceutical marketers a new way to think about treatment value.
The most meaningful product benefit may sometimes be the chemotherapy, radiation, surgery, or disruption that certain patients can avoid.
However, that potential must always be communicated within the limits of the approved indication and clinical evidence.
Marketing treatments that may reduce the need for intensive medical care is not about celebrating fewer interventions at any cost. Instead, it is about explaining how appropriate treatment choices may reduce unnecessary burdens while maintaining a strong focus on cancer control.
For pharmaceutical brands, the larger lesson is clear: innovation is not always defined by what medicine adds to a patient’s life. Sometimes, its value lies in what a patient may no longer need to endure.
Frequently Asked Questions
What does treatment deintensification mean in pharmaceutical marketing?
It means communicating the potential value of reducing or avoiding certain medical interventions when supported by clinical evidence. The focus is on patient experience, treatment burden, and meaningful outcomes without overstating benefits.
Why is Jemperli important for rectal cancer treatment?
Jemperli offers an FDA-approved immunotherapy option for adults with stage II or III dMMR/MSI-H locally advanced rectal cancer. Some eligible patients may avoid chemotherapy, radiation, and surgery, although further follow-up is needed to confirm long-term benefits.
Can Jemperli eliminate the need for rectal cancer surgery?
Some patients in clinical studies avoided surgery following Jemperli treatment. However, surgery or other therapies may still be needed if the cancer does not respond adequately or later returns. Individual treatment decisions require specialist evaluation.
How can pharmaceutical marketers promote less intensive cancer treatments responsibly?
Marketers should use accurate clinical evidence, explain patient eligibility, communicate treatment risks, and distinguish potential benefits from guaranteed outcomes. Promotional claims must also follow FDA requirements for truthful, balanced prescription drug advertising.
Why does avoiding treatment matter to patients?
Avoiding certain interventions may reduce physical side effects, recovery demands, financial burdens, and disruption to daily life. However, the benefits depend on individual circumstances, treatment response, and continued medical monitoring.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
